Sökning: id:"swepub:oai:DiVA.org:uu-17445" >
Individually tailor...
Individually tailored toxicity-based 5-fluorouracil, epirubicin and cyclophosphamide (FEC) therapy of metastatic breast cancer
-
- Lindman, Henrik (författare)
- Uppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi,Bröstgruppen
-
- Åström, Gunnar (författare)
- Uppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi
-
- Ahlgren, Johan (författare)
- Uppsala universitet,Centrum för klinisk forskning, Gävleborg,Bröstgruppen
-
visa fler...
-
- Villman, Kenneth (författare)
- Uppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi,Bröstgruppen
-
- Blomqvist, Carl (författare)
- Uppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi,Bröstgruppen
-
- Nygren, Peter (författare)
- Uppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi,GI
-
- Bergh, Jonas (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- 2009-07-08
- 2007
- Engelska.
-
Ingår i: Acta Oncologica. - : Informa UK Limited. - 0284-186X .- 1651-226X. ; 46:2, s. 165-171
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Chemotherapy dosing only based on body surface area (BSA) results in marked pharmacokinetic and toxicity variations, which may result in an inferior outcome for some patients. A toxicity-based dosing schedule for individually tailored treatment with granulocyte colony-stimulating factor (G-CSF) supported 5-fluorouracil (F), epirubicin (E) and cyclophosphamide (C) (dFEC) was developed and studied in patients with metastatic breast cancer with the purpose to determine its efficiency and toxicity. Twenty-six women, median age 48 years, were included and the individual E and C doses were tailored stepwise based on the recorded hematological toxicity. Twenty-one patients (81%; 95% confidence interval (CI), 66% to 96%) had an objective response, including six complete responses (23%; CI, 7%-39%). At median follow-up of 113 months, the median time to progression and median overall survival were 14 and 36 months, respectively. The delivered dose intensity was high but varied substantially between patients (ranges F 126-202, E 14.4-36.0, C 160-510 mg/m2/w). The dominating grade III/IV toxicity was nausea (12% of patients) and febrile neutropenia (31% of patients). The tailored and dose-escalated FEC was highly active and feasible in metastatic breast cancer and may provide a pragmatic way of overcoming the shortcomings of standard BSA-based dosing.
Nyckelord
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas